attenuates hypoxic pulmonary hypertension via enhanced nitric oxide signaling and the erythropoietin system.
CHRONIC ALVEOLAR HYPOXIA IS likely to initiate hypoxic pulmonary vasoconstriction (32) and chronic structural remodeling of those vessels, possibly contributing to chronic hypoxia-induced pulmonary hypertension (hypoxic PH) (39) . In fact, the presence of PH at diagnosis of respiratory diseases is considered a critical determinant of prognosis (2, 6) . The endothelial dysfunction that accompanies hypoxic PH has been attributed to a decreased production and release of the endotheliumderived vasodilator, primary nitric oxide (NO) (21) . NO is produced mostly by endothelial NO synthase (eNOS), and efficient production of NO requires the phosphorylation of eNOS (p-eNOS) at Ser 1177 by serine/threonine kinase Akt, a downstream target of phosphatidylinositol 3-kinase (PI3K) (7, 11, 28) . Although the expression of eNOS and production of NO declined in hypoxic PH patients (13, 14) , the opposite condition-enhancement of NO production or preservation of eNOS expression, as well as phosphorylation-actually lessened the progress of hypoxic PH (29) .
Hypoxic polycythemic responses to erythropoietin (EPO) have long been believed to raise pulmonary vascular resistance, leading to the development of PH and failure of the right heart. However, polycythemia did not augment the severity of hypoxic PH in some experiments with rats (30) . Additionally, an important, protective role for the vascular EPO/EPO receptor (EPOR) system was found to offset insultus from chronic hypoxia and ischemia (37, 38) . EPOR is expressed on cardiomyocytes, cardiac fibroblasts, endothelial cells, and vascular smooth muscle cells (22) . The phosphorylation of EPOR generates a variety of signaling molecules, such as PI3K (10) , which inhibit apoptosis, induce cell proliferation, and promote p-eNOS (1, 43) . In vivo, EPO treatment beneficially reduced the severity of pulmonary vascular and cardiac remodeling of the subjects with experimental PH (31, 44) . In endothelial cells, both EPO and hypoxia increased EPOR and eNOS expression (3) . In addition, a combined treatment with EPO and sildenafil acted synergistically to restore endothelial function after hypoxic exposure (12) . These results indicate that the EPO/EPOR system has potential as a new therapeutic agent by virtue of its ability to activate NO-mediated signaling in victims of hypoxic PH.
Genistein (Gen), a phytoestrogen derived from soybeans and tested in numerous studies, has been shown to have vasodilative and cardioprotective effects. Gen enhanced eNOS activity and NO-mediated vasorelaxation, not only in the systemic circulation (40) but also in pulmonary arteries, independently of any estrogen-mediated mechanism (18) . In addition, we previously found that a 21-day treatment with Gen significantly attenuated the development of monocrotaline (MCT)-induced PH in rats, another model of PH, by restoring eNOS expression (16) . Therefore, this study was designed to investigate whether treatment with Gen would attenuate hypoxic PH through amelioration of the EPO/EPOR system and NO-mediated signaling.
MATERIALS AND METHODS
Animals and exposure to chronic hypoxia. All experimental and surgical procedures were approved by the Institutional Committee for "Use and Care of Laboratory Animals in Juntendo University" (Hongo, Tokyo, Japan), in accordance with the U.S. National Institutes of Health "Guide for the Care and Use of Laboratory Animals." Experiments were performed with adult male Sprague-Dawley rats (200 -250 g) obtained from Charles River Laboratories (Yokohama, Japan).
The pulmonary normotensive rats (the control group; NL) were housed at the ambient barometric pressure (760 mmHg). Chronically hypoxic pulmonary hypertensive rats (the experimental group; HL) were housed in a hypobaric chamber (barometric pressure, ϳ380 mmHg; inspired O 2 tension, ϳ76 mmHg), which was flushed contin-uously with room air to prevent accumulation of CO2, NH3, and H2O for a period of 21 days, as described previously (25) .
Animal experimental protocols. For these studies, rats were randomly assigned to one of the following four groups (n ϭ 6 -8 animals in each group) to be administered either vehicle or Gen (60 mg/kg; Sigma Chemical, St. Louis, MO) (39): 1) control animals raised in normoxia; 2) Gen-treated animals raised in normoxia; 3) control animals raised in chronic hypoxia; 4) Gen-treated animals raised in chronic hypoxia. For treatment, Gen was dissolved in a mixture of DMSO (Sigma Chemical) and polyethylene glycol (PEG; Sigma Chemical). Rats were given subcutaneous injections of Gen or vehicle (100 l of a mixture containing 1.25% DMSO and 98.75% PEG) daily throughout the experiments.
The efficacy of dietary Gen by gavage was also evaluated throughout the additional experiments. The Gen dosage of 60 mg/kg by gavage once/day was given to rats during hypoxic exposure for 3 wk. For comparison of the plasma concentrations of Gen between the control sample, subcutaneous and dietary delivery was examined by using the Gen TR-FIA (Labmaster, Aura, Finland) at the end of hypoxic exposure.
Hemodynamic measurements. Animals were anesthetized by intraperitoneal injection with pentobarbital sodium (15 mg/kg) and implanted with catheters in the pulmonary and right carotid arteries and right jugular vein, as described previously (16) . Right ventricular systolic pressure (RVSP) and systemic arterial pressure (SAP) were measured with a polygraph system (AT-600G cardiotachometer; Nihon Kohden, Tokyo, Japan).
Measurement of RV hypertrophy. Each heart was dissected to assess the severity of PH. An index of RV hypertrophy was calculated as the ratio of wet weight of the RV wall to wet weight of the left ventricular (LV) wall plus septum (RV/LV ＋ S).
Morphological studies. At the end of each hemodynamic study, the rats were killed with an overdose of pentobarbital sodium, and the thorax was opened. After blood samples were drawn from the right ventricle, the heart and lungs were removed en bloc. The trachea was intubated, and the left lung was inflated with 10% formalin at 36 cm H 2O pressure and fixed in the inflated state for 3 days. The right lung was frozen in liquid nitrogen for further molecular analysis.
Sections of pulmonary arteries were treated with elastic van Gieson stain for morphometric analysis of the arteries' medial-wall thickness to assess the degree of their muscularization, as described previously (16) . In each tissue section, at least 50 consecutive arteries (Ͼ30 m external diameter) were examined at ϫ400 magnification using an image analysis system (KS400; Carl Zeiss Imaging Solutions GmbH, Hallbergmoos, Germany). The medial-wall thickness was measured at two locations of each artery and calculated according to the following formula: (medial-wall thickness/external diameter) ϫ 100 (in percent).
Pulmonary sections were also stained with EPOR antibody (1:50, anti-EPOR; Santa Cruz Biotechnology, Dallas, TX) to quantitate the EPOR immunoreactions. The paraffin-embedded, formalin-fixed lung specimens were washed and incubated with EPOR antibody overnight, followed by a 30-min incubation with the secondary antibody (1:300, biotinylated goat anti-rabbit IgG; Dako, Produktionsvej, Denmark). The color reaction was performed with 3,3-diaminobenzine. For quantitative analysis of the proportion of the EPOR immunoreaction, we counted the number of EPOR-positive endothelial cells of all endothelial cells in 50 consecutive pulmonary arteries within a size of 30 -120 m external diameter.
Vascular responses in isolated perfused lung. The rapid vasodilative effects of Gen were investigated in isolated perfused rat lungs, as described previously with minor modifications (24, 25) . Lungs were harvested from NL and HL rats (n ϭ 6 -8 animals in each group) and ventilated with 21% O2-5% CO2-74% N2 and perfused in a recirculating system. Effluent perfusate was drained from LV cannula into a perfusate reservoir, and the perfusate reservoir volume was monitored continuously. The perfusate was a physiological salt solution containing 116.3 mM NaCl, 5.4 mM KCl, 0.83 mM MgSO4, 19.0 mM NaHCO 3, 1.04 mM NaH2PO4, 1.8 CaCl2· 2 H2O, and 5.5 mM D-glucose (Earle's balanced solution). Ficoll (4 g/100 ml, type 70; Pharmacia, Uppsala, Sweden) was included as a colloid. Before starting all experiments, 3.1 mol/l sodium meclofenamate (Sigma Chemical) was added to inhibit synthesis of vasodilator prostaglandins (27, 36) .
Initial experiments compared the vasoconstriction in responses to KCl (Sigma Chemical) of lungs from NL and HL rats. After equilibration, 5ϳ20 mmol/l KCl was added to the perfusate in a concentration-response fashion every 5th min. Higher concentrations of KCl were not used because they caused lung edema. We next tested whether Gen has acute vasodilative effects against KCl-induced vasoconstriction in NL and chronic hypoxia lungs. At the peak of the KCl pressor response, 30 mol/l Gen or vehicle (DMSO) was added to the perfusate. We also tested whether N G -nitro-L-arginine (NLA; Sigma Chemical), an inhibitor of NOS, blocks the vasodilative response to Gen. NLA (200 mol/l) was added to the perfusate at 20 min after administration of Gen or vehicle. Vascular effects were analyzed by measuring baseline perfusion pressure, peak KCl pressor response, the ratio of spontaneous (vehicle) or Gen-induced vasodilation to the KCl-induced vasoconstriction, and NLA-induced vasoconstriction. The ratio of vasodilation was calculated by dividing the decrease in pressure occurring from the addition of either vehicle or Gen to the perfusate at the peak of the KCl pressor response by the magnitude of the KCl pressor response.
To confirm further the mechanism in vascular responses to Gen, we examined whether the vasodilative effect of Gen was mediated by a PI3K/Akt-dependent pathway. LY294002, a specific PI3K inhibitor (10 mol/l; Cayman Chemical, Ann Arbor, MI), was added to the perfusate at the peak of the KCl pressor response before the administration of Gen in separate experiments. Then, the alteration in vasodilative effect of Gen caused by the PI3K inhibitor was calculated as the ratio of vasodilation. To control for differences in vasoreactivity over time of perfusion, the inhibitor, antagonist, or respective vehicle was administrated identically with respective time.
cGMP measurement by enzyme immunoassay. cGMP levels in lung tissue were determined by the cGMP enzyme immunoassay (EIA; Cayman Chemical), according to the manufacturer's instructions, as described previously (20) . The sample cGMP concentration was determined (as fmol/mg tissue) using the equation obtained from a standard curve. Each sample was evaluated in duplicate, and the process was repeated three times.
Western blots. Frozen lung tissues and pulmonary arteries were homogenized in lysis buffer containing 10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 1% Triton X-100, and 1 mM protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN) using a tissue homogenizer. Samples were centrifuged for 15 min at 15,000 g at 4°C, and the supernatant protein concentration was estimated using a Micro BCA Protein Assay Reagent Kit (Pierce Biotechnology, Rockford, IL). Equal amounts of protein suspensions were separated electrophoretically on 5ϳ10% SDS-polyacrylamide gels and transferred to polyvinylidene difluoride transfer membranes (GE Healthcare UK, Buckinghamshire, UK). Subsequently, the membranes were provided with anti-eNOS antibody (BD Biosciences, Franklin Lakes, NJ) or anti-peNOS (Ser 1177 ; Cell Signaling Technology, Danvers, MA). Signals were visualized by the ECL Prime detection system (Amersham Biosciences, GE Healthcare, Uppsala, Sweden). The protein bands were quantified using ImageJ software (version 1.43u).
Cells and cell culture. Human umbilical vein endothelial cells (HUVECs; Clonetics, Walkersville, MD) were cultured in 25-cm 2 flasks with a phenol red-free endothelial basal medium-2 (Lonza, Walkersville, MD) Bullet Kit, supplemented with endothelial growth medium 2 (Lonza, Basel, Switzerland) containing 5% FBS and cytokines. The human hepatoma cell line (HepG2; American Type Culture Collection, Manassas, VA) was cultured in DMEM containing 10% FBS. The medium was changed each day, and cells were used within three to five passages. Cells were incubated under both 21% (normoxia) and 1% (hypoxia) oxygen for 48 h and were washed in HEPES buffer before exposure to hypoxia.
Combined treatment with Gen and EPO and protein analysis of HUVECs. HUVECs were cultured with the medium, which was replaced with or without 5 U/ml EPO and 10 mol/l Gen for a 48-h exposure to the normoxia or hypoxia environment. Cells were washed and scraped from the plate, and the lysate was centrifuged for 15 min at 15,000 g at 4°C. The supernatant protein concentration was then estimated using a Micro BCA Protein Assay Reagent Kit (Pierce Biotechnology).
Measurement of EPO production in the culture supernatant of HepG2 cells under hypoxia. HepG2 cells were plated at a density of 5 ϫ 10 5 cells/35 mm dish. At 24 h after the onset of culture, the medium was replaced with or without 10 M Gen and then incubated for 48 h of exposure to normoxia or hypoxia. EPO protein concentration in the HepG2 cell culture supernatant was determined by chemiluminescent EIA by using Access EPO (Beckman Coulter, Brea, CA) as described previously (5).
Data analysis. Data are presented as means Ϯ SE. Statistical analysis was done by unpaired t-test or one-way ANOVA, followed by Tukey's multiple comparisons test, or two-way ANOVA, followed by the Bonferroni test (Prism 5; GraphPad Software, San Diego, CA). Differences were considered significant at P Ͻ 0.05.
RESULTS
Treatment with Gen ameliorated hypoxic PH by restoring hemodynamics, preventing RV hypertrophy, and averting vascular remodeling. Exposure to conditions of chronic hypoxia caused severe PH; that is, HL rats had 50.6 Ϯ 4.32 mmHg of peak RVSP compared with 9.6 Ϯ 0.74 mmHg of peak RVSP in NL rats (P Ͻ 0.05, n ϭ 11ϳ12). Gen significantly attenuated the elevation of RVSP in HL rats but did not affect the peak RVSP in NL rats (Fig. 1A) . SAP and heart rates (HR) were similar in all groups (Fig. 1, B and C) . The severity of PH was confirmed further by RV hypertrophy (RV/LV ϩ S); that is, the RV value of 0.52 Ϯ 0.02 in HL rats was increased significantly over that of 0.25 Ϯ 0.01 in NL rats (P Ͻ 0.05, n ϭ 11ϳ12). Gen diminished the increase in RV/LV ϩ S in the HL bearers but did not affect their NL counterparts (Fig. 1D) .
Dietary Gen by gavage also attenuated the magnitude of RV/LV ϩ S but did not affect the elevation of RVSP in HL rats (Fig. 1, E and F) . However, dietary Gen did not alter RVSP or RV/LV ϩ S in the NL group. The plasma concentration was lower in gavage than in subcutaneous delivery (27.1 Ϯ 21.2 nmol/l, 970.3 Ϯ 549.7 nmol/l, and 398.2 Ϯ 338.8 nmol/l, respectively, for control, subcutaneous, and gavage delivery; P Ͻ 0.05, n ϭ 5-7/each group). The coefficient of variation of the concentrations were 77.9%, 56.7%, and 85.1%, respectively, for control, subcutaneous, and gavage delivery (Fig. 1G) .
In the hypoxic condition, medial-wall thickness of muscular pulmonary arteries corresponding to terminal bronchioles was increased significantly when compared with that of NL animals. However, Gen treatment reduced the increase in medialwall thickness of each vessel (vessel diameter of 30ϳ60 m, 60ϳ120 m, and Ͼ120 m) in HL rats (Fig. 2, A-D) .
Gen restores cGMP levels and preserves p-eNOS at Ser 1177
in hypoxic PH. To determine the cellular and molecular mechanisms used by Gen to lessen experimental hypoxic PH, we quantitated cGMP levels in lungs of all four groups used here. The cGMP levels in the whole lung were clearly lower in HL compared with NL tissues; comparatively, Gen preserved cGMP levels in lungs from the HL group. However, Gen increased cGMP levels slightly but not significantly in lungs from the NL group (P Ͻ 0.05, n ϭ 6ϳ8; Fig. 3A) .
To examine the effects of Gen on eNOS and Akt activity, we assessed the p-eNOS at Ser 1177 and p-Akt at Ser 473 in lungs and pulmonary arteries. The representative Western blot analyses of lung homogenates are shown in Fig. 3 , B-E. Although protein expression of eNOS or Akt, respectively, was increased or unaltered, the p-eNOS at Ser 1177 and p-Akt at Ser 473 decreased significantly in not only lungs but also pulmonary arteries from HL compared with NL rats. Gen attenuated the decrease in expression of p-eNOS but not p-Akt in the lungs manifesting HL but increased the expression of both p-eNOS and p-Akt in pulmonary arteries from the HL group. These results suggest that Gen restored the expression of both peNOS and p-Akt selectively in pulmonary arteries.
Gen causes rapid vasodilation in isolated perfused lungs from NL and HL rats.
In preparation for analyses of vasoconstriction and dilation, baseline levels were established. In 12ϳ16 animals/group, we noted that the perfusion pressure was higher in vessels from HL rats (7.93 Ϯ 0.37 mmHg) than in NL rats (6.25 Ϯ 0.28 mmHg; P Ͻ 0.05, n ϭ 12ϳ16). Subsequently, KCl caused a concentration-dependent vasoconstriction that was greater in the HL group compared with NL animals (Fig. 4A) . These results suggested the presence of increased vascular tone and abnormal vasoconstriction in pulmonary vessels during the course of HL. However, in the presence of KCl-induced vasoconstriction, Gen caused a similar extent of vasodilation in NL and HL vessels (Fig. 4B) .
Rapid vasodilative effect of Gen is abolished by either NLA or a specific PI3K/Akt kinase inhibitor. The effect of Geninduced vasodilation on KCl-induced vasoconstriction was abolished completely after NLA administration into the lungs of NL and HL rats (Fig. 4C) . Pretreatment with LY294002, a specific PI3K/Akt kinase inhibitor, blunted the vasodilative effect of Gen significantly in both the NL and HL (Fig. 4D) . These results suggest that the mechanism of a Gen-induced vasodilative effect was dependent on eNOS but, at least in part, mediated through the PI3K/Akt pathway.
Gen increases hemoglobin concentration, hematocrit levels, EPO production, and EPOR-positive endothelial cell counts of pulmonary arteries in hypoxic PH. Prolonged exposure to a hypoxic condition caused a significant increase of the hemoglobin (Hb) concentration and hematocrit (Hct) levels (17.10 Ϯ 1.50 g/dl and 51.30 Ϯ 4.16%, respectively) in the HL group above that in NL subjects (13.24 Ϯ 1.12 g/dl and 39.72 Ϯ 3.81%, respectively; P Ͻ 0.0001, n ϭ 5-6). Gen potentiated the hypoxic increase of Hb concentration and Hct levels (Fig. 5, A and B) .
Similar to the rise in Hb concentrations and Hct levels, Gen potentiated the increases of serum EPO levels and percentages of EPOR-positive endothelial cells. That is, EPO was 18.98 Ϯ 6.45 mU/ml for HL vs. 40.73 Ϯ 14.82 mU/ml for HL Gen (P Ͻ 0.05, n ϭ 8), and percentages of EPOR-positive endothelial cell counts were 20.84 Ϯ 7.38% for HL vs. 33.32 Ϯ 6.06% for HL Gen (P Ͻ 0.0001, n ϭ 4 -6; Fig. 5, C-E) . However, Gen did not affect Hb concentrations, Hct levels, EPO levels, or EPOR-positive endothelial cell counts in the NL groups.
EPO combined with Gen increases the p-eNOS at Ser 1177 and EPOR expression in HUVECs under hypoxic exposure.
Since exogenous EPO (5 U/ml) and hypoxia (2% O 2 ) for 48 h increased expression of eNOS and EPOR in HUVECs (3), we examined whether Gen (10 mol/l) would potentiate the peNOS at Ser 1177 and the expression of EPOR in cultured HUVECs for 48 h under 1% O 2 exposure with EPO (5 U/ml). Whereas 10 mol/l Gen but not 5 U/ml EPO increased the p-eNOS at Ser 1177 , the combined administration of EPO and Gen further potentiated the p-eNOS at Ser 1177 under hypoxic exposure (Fig. 6A) . In addition, 10 mol/l Gen alone and the combination of 10 mol/l Gen and 5 U/ml EPO but not EPO alone upregulated EPOR protein expression, as shown by Western blot analysis in HUVECs under hypoxic exposure (Fig. 6B) .
Hypoxia and Gen further increase EPO production in HepG2 cells. The human hepatoma cell lines, HepG2 and Hep3B, are widely used models for studying the production of EPO under hypoxic conditions. The mechanism is dependent on normal glycosylation of EPO, accumulation of cAMP, and interaction of cGMP and NO (26, 42) . In our experiments, 1% O 2 exposure for 48 h induced a significant increase in EPO production in the culture medium from HepG2 cells compared with cells in a state of normoxia. Resulting values were 1.20 Ϯ 0.00 mU/ml for normoxia vs. 5.57 Ϯ 1.40 mU/ml for hypoxia (P Ͻ 0.05, n ϭ 4). The addition of Gen (10 mol/l) enhanced the production of EPO in HepG2 cells under hypoxic exposure (9.63 Ϯ 2.37 mU/ml for hypoxia Gen vs. 5.57 Ϯ 1.40 mU/ml for hypoxia; P Ͻ 0.05, n ϭ 4; Fig. 6C ). However, Gen did not affect EPOR expression in HUVECs or EPO production in HepG2 cells under normoxic exposure.
DISCUSSION
In the present study, we demonstrate clearly that Gen is capable of attenuating hypoxic PH by correcting its chronic structural remodeling component and also its abnormal vasoconstrictive component in the lungs. In addition, for the first time, we showed that the EPO/EPOR system and PI3K/Akt pathway are likely contributors to the ability of Gen to improve NO-mediated signaling.
In the pathogenesis of hypoxic PH, reduced NO-mediated vasodilation is a major factor in the impairment of endothelialdependent vasodilation (15) . This impaired vasodilation occurs in not only chronically hypoxic animal models but also patients with chronic obstructive lung disease and pulmonary arterial hypertension (4, 19) . The defect in responsiveness to endothelium-dependent vasodilation is thought to be a consequence of reduced cGMP activity and of downstream NO production in hypoxic PH (8) . In other words, the normalizing of NOmediated signaling may contribute to attenuating hypoxic PH.
Chronic hypoxia-induced EPO production is a critical factor in the proliferation of red blood cells, and this response is traditionally believed to raise pulmonary vascular resistance, leading to the development of PH. In that context, the vascular EPO/EPOR system was recently invoked as a novel therapeutic target for cardiovascular disease (37) . p-EPOR initiates a variety of signaling pathways, including PI3K, which is involved in NO-mediated signaling (23) . In addition, in vivo studies showed that the effect of EPO on eNOS may be a physiologically relevant mechanism to counterbalance hypoxia (3).
The beneficial effects of Gen on cardiovascular diseases (9, 41) have been established and featured less toxicity and drug interactions than other treatments. Studies have shown that Gen interacted with vascular endothelial cells directly and increased NO production independently via an estrogen-mediated mechanism (31a, 45). We found that Gen significantly downregulated the development of MCT-induced PH by restoring eNOS expression in the lungs (16) . These results indicate the strong potential of Gen as a therapeutic option for patients with hypoxic PH by virtue of its ability to mediate NO signaling and the EPO/EPOR system.
Long-term treatment with Gen restored normalcy to pulmonary hemodynamics and vascular remodeling, whereas a single dose of Gen produced rapid vasodilation to counterbalance vasoconstriction in this model. In experiments with isolated lungs perfused with a physiological salt solution, HL rats underwent elevations of baseline pressure, presumably produced by the increase in pulmonary resistance, resulting from vasoconstriction and vascular remodeling. In addition, the greater KCl pressor response of these HL animals indicated augmentation of abnormal vasoconstriction, probably caused by boosting vascular tone in subjects exposed long-term to a low-oxygen environment.
Gen administered directly into the isolated perfused lung yielded a virtually immediate vasodilative effect that offset the abnormal augmentation of vascular tone in HL lungs. Since Gen-induced vasodilation was reduced by the NOS and PI3K inhibitors, apparently such vasodilation is dependent on PI3K/ Akt-and NO-mediated signaling.
The present study showed that Gen suppressed the elevation of RVSP without causing systemic hypotension, reduced the HR, and prevented vascular remodeling in whole pulmonary arteries. It is generally agreed that the exacerbation of right heart failure caused by the elevation of RVSP and the systemic hypotension occurring after a decrease in cardiac output predispose PH patients to a fatal outcome. Because Gen did not affect the systemic blood pressure or the HR, Gen is a potentially useful agent for the prevention and treatment of hypoxic PH.
Mechanisms of Gen in preventing PH. We found that Gen restored levels of cGMP and p-eNOS at Ser 1177 and p-Akt at Ser 473 in hypoxic lungs and pulmonary arteries. The protein kinase Akt has been proposed to phosphorylate eNOS at Ser 1177 and to increase eNOS activity in response to various stimuli in vascular endothelial cells (7), whereas Gen activated eNOS through a PI3K/Akt-dependent mechanism in pulmonary arterial endothelial cells (45) . For the first time, however, the present study of HL rats demonstrated that Gen treatment upregulated the PI3K/Akt pathway in the lungs and pulmonary arteries. Since the vasodilative effect of Gen was abolished by administration of a NOS or PI3K/Akt inhibitor in isolated perfused lungs, Gen treatment may be attributable to the improvement of NO-mediated signaling, mostly through an Akt-dependent mechanism. In fact, Gen restored the p-eNOS at Ser 1177 and p-Akt at Ser 473 in hypoxic lungs manifesting PH and pulmonary arteries from HL rats.
Here, Gen treatment enabled an increase in Hb concentration and Hct levels in association with upregulation of EPO in serum and EPOR expression in endothelial cells of pulmonary arteries. The mechanism of action of Gen in pulmonary vasculature may function through the EPO/ EPOR system. In vitro, 10 mol/l Gen increased the peNOS at Ser 1177 and EPOR expression in hypoxic HUVECs, as well as the production of EPO in hypoxic HepG2 cells. With the consideration of these results, Gen treatment may improve eNOS activities and upgrade the EPO/EPOR system, even though hypoxia is present.
Although our results raise the possibility that eNOS and the EPO/EPOR system are needed to improve each other under Gen treatment, the precise mechanism of their interaction is still unclear. The interaction of NO and cGMP is one of the pathways of hypoxia-induced stimulation of EPO gene expression (26) . Administration of NLA, a NOS inhibitor, inhibited EPO production, although pretreatment with L-arginine prevented the inhibition (17 (3), transgenic mice overexpressing EPO produced increased amounts of eNOS activity (34) . Since that observation is compatible with ours, the present study suggests that Gen may be effective in promoting the EPO/EPOR system, thereby ameliorating the interaction between EPO and eNOS.
Limitations. There are limitations of this study. First, in isolated perfused lung experiments, we used a Hb-free physiological saline solution for perfusate. It has the possibility that the half-life of circulating NO is able to prolong and that the decreased clearance of NO may enhance the dilator response to Gen. Second, although the PH model demonstrated several main features of hypoxic PH, such as vascular remodeling and endothelial dysfunction, no plexiform lesions were seen, which is a hallmark feature of vasculature in pulmonary arterial hypertension and fatal PH patients, in the present study. Third, the cardiac output was not estimated directly as hemodynamic measurements. Although Gen demonstrated no obvious effects on systemic blood pressure and HR, we cannot exclude a possibility that decreased cardiac output may contribute to the reduction of RVSP. Fourth, in in vitro studies, HUVECs and the HepG2 cell line did not necessarily accord with pulmonary arterial endothelial cells because of some difference of property between them. Fifth, the present study did not delineate the exact relationship between the increase in p-Akt at Ser 473 and p-eNOS at Ser 1177 . Finally, the efficacy of Gen by other delivery, for example, dietary or inhalation, should be examined, because subcutaneous delivery was not necessarily pertinent. There raises a possibility of Gen as a promising option for treatment of hypoxic PH, since dietary Gen also attenuated RV hypertrophy of HL animals. However, contrary to subcutaneous delivery, dietary Gen did not affect the elevation of RVSP of HL animals. Although the reason of discrepancy was unclear, the lower and more inconsistent plasma concentration of dietary Gen may account for the different effects between subcutaneous and dietary delivery. On the other hand, as gut absorption and metabolism influenced large individual variation of plasma concentrations of Gen (33) , suitable delivery of dietary Gen could answer these concerns. Further studies are required to elucidate these questions.
Conclusions. In the pathogenesis of hypoxic PH, endothelial cell dysfunction, characterized by the impairment of NOmediated signaling, has been suggested to provoke abnormal vasoconstriction and vascular remodeling. Enhancement of the EPO/EPOR system in hypoxic conditions is thought to be a purposeful alteration that ameliorates endothelial function through upregulation of NO-mediated signaling. Our present study demonstrated for the first time that Gen, a phytoestrogen derived from soybeans, attenuated hypoxic PH by preventing vasoconstriction and chronic structural remodeling through restoration of NO-mediated signaling. In addition, Gen treatment enhanced the EPO/EPOR system function in the lungs and endothelial cells of pulmonary arteries from subjects with hypoxic PH. From these cumulative results, we envision that Gen may orchestrate the restoration of PI3K/Akt-dependent, NO-mediated signaling and enhancement of EPO/EPOR function, thereby preventing hypoxic PH. Based on our results and previous studies, combined with further examination and clinical studies, we propose that Gen may be an effective and safe option for the treatment of patients with hypoxic PH.
